Biotech and Micro-Cap Stocks Surge Amid Market Rally
By ATTN Desk · Editorial oversight: Sean Han
Daily Market Recap: July 23, 2025
Today’s session saw broad-based gains across small-cap and micro-cap names, with every stock in our coverage posting double-digit advances. High-volume spikes in technology, biotech, and real-estate REITs underscored a risk-on tone as investors cheered clinical milestones, strategic partnerships, and financing initiatives.
| Ticker | ATTN Price | Current Price | Volume | Price Change % |
|---|---|---|---|---|
| AMOD | 1.0655 | 1.7207 | 84,418,145 | 61.49% |
| OFAL | 1.8526 | 2.2200 | 10,473,333 | 19.80% |
| ANEB | 2.9973 | 3.3400 | 9,968,595 | 11.40% |
| CLSD | 0.4263 | 0.5821 | 132,777,641 | 36.57% |
| VICR | 42.9439 | 52.9600 | 1,767,987 | 23.24% |
| DNUT | 3.0998 | 4.2997 | 98,605,712 | 38.74% |
| HCTI | 0.0195 | 0.0253 | 553,098,997 | 29.55% |
| MKZR | 0.2874 | 0.7137 | 5,883,154 | 148.53% |
| PRPL | 0.7802 | 0.9571 | 3,075,621 | 22.73% |
| ZOOZ | 1.9350 | 3.1000 | 9,745,138 | 60.19% |
| CTOR | 1.0650 | 1.7800 | 13,771,761 | 67.06% |
| ATYR | 5.3909 | 6.6000 | 13,536,098 | 22.41% |
| IOVA | 3.3579 | 4.0600 | 77,181,444 | 20.95% |
| PALI | 0.7168 | 1.1400 | 8,692,966 | 59.06% |
| RNAZ | 6.8301 | 11.0900 | 2,837,144 | 62.34% |
| REPL | 2.3071 | 3.2900 | 30,200,139 | 42.59% |
| SHOT | 0.5884 | 0.9107 | 13,972,047 | 54.79% |
| CYCC | 9.8267 | 14.0800 | 1,231,187 | 43.33% |
| ZSPC | 2.5959 | 3.8200 | 284,218 | 47.16% |
Market Trends and Patterns
Today’s rally was driven by strong performance in speculative-grade sectors, particularly biotech and micro-cap technology. Low-priced names (<$5) led the advance, as traders chased high-beta opportunities. Volume was exceptionally heavy in sub-penny and sub-$1 stocks, highlighting aggressive retail participation. Mid-cap REITs and specialty finance issuers also outperformed, supported by refinancing announcements and capital raises.
Trading activity skewed toward names with recent corporate developments:
- HCTI and DNUT both saw volumes above 90 million shares as investors rotated into high-yield biotech prospects.
- CLSD and AMOD traded in excess of 80 million shares, reflecting renewed interest in retail-tech and litigation-funding businesses.
- VICR and IOVA each posted over 70 million in volume, underscoring strength in industrial technology and medical device sectors.
Notable Movers
Several companies stood out for exceptional gains and key catalysts:
• MACKENZIE Realty Capital (MKZR): Surged 148.53% to $0.71 after completing a strategic debt refinancing, bolstering its balance sheet for planned West Coast expansions.
• Citius Oncology (CTOR): Jumped 67.06% to $1.78 as it secured SEC clearance for a $9 million public offering and finalizes U.S. launch preparations for its LYMPHIR immunotherapy.
• TransCode Therapeutics (RNAZ): Climbed 62.34% to $11.09 on positive clinical updates for TTX-MC138 and new partnership agreements accelerating development timelines.
• Alpha Modus Holdings (AMOD): Rose 61.49% to $1.72 following announcements of expanded licensing deals in AI-driven retail solutions and strengthening of its patent portfolio.
• ZOOZ Power (ZOOZ): Advanced 60.19% to $3.10 after SEC granted F-3 registration statement effectiveness, paving the way for a new funding round to scale its EV‐charging storage systems.
Market Rally by Rafelia Kurniawan
TL;DR
- All 19 tracked stocks closed higher, with gains ranging from +11.40% to +148.53%.
- Sub-$5 names and biotech plays led volume surges; HCTI, DNUT, and CLSD each traded over 90 million shares.
- MKZR and CTOR reported refinancing and financing deals that fueled their respective rallies.
- Clinical milestones propelled RNAZ, while licensing and patent expansions lifted AMOD.
- SEC approval energized ZOOZ ahead of its next capital raise.